AIVIS is a leading digital pathology company specializing in AI-driven automated biomarker quantification. With a multidisciplinary team of pathologists, AI researchers, and software engineers, AIVIS integrates clinical insight into applied AI solutions. Its flagship product, Qanti® IHC, can quantitatively analyze clinically useful immunohistochemistry (IHC) biomarkers, including Ki-67 and HER2. By standardizing IHC interpretation, Qanti® significantly reduces inter-observer variability and delays in cell counting, enabling pathologists to make timely diagnoses for patients. Qanti® IHC has received in vitro medical device approvals and reimbursement in South Korea, along with GMP and ISO 13485 certifications. It currently supports the daily practice of pathologists in over 20 hospitals and medical institutions worldwide. With its smart AI quantification solution, AIVIS delivers reproducible and accurate biomarker assessments, contributing to the advancement of precision oncology.
